TICKERNERD
Menu
PLSEPLSEHealthcare · Medical Instruments & Supplies

PLSE Stock Forecast: Pulse Biosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$54
+2.07% on the day

The 5 Wall Street analysts covering Pulse Biosciences, Inc. hold a median 12-month price target of $45 — -17.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 14 Sept 2026 — in the lower half.

Market cap
$3.9B
Ticker Nerd rank
42 / 100
Median analyst target
$45
Analysts covering
5
Revenue$434K
Operating income−$25.3M
Net income−$24.7M
Free cash flow−$18.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.8%
1M
+21.7%
YTD
+294.8%
1Y
+273.3%
From 52W high
−0.9%
From 52W low
+328.2%
$13
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PLSE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pulse Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Accruals
80
Issuance
59
Revisions
54
Growth
37
Value
34
Size
27
Volatility
27
Quality
12

Momentum (99): The shares have been drifting up relative to others.

Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLSE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLSE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26PLSEHigh $73Median $45Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $35Median $45High $73

The green dot is the last close — the median target sits −17.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Sept 2026Freedom Capital MarketsInitiatesBuy$73
17 Aug 2026NeedhamInitiatesBuy$58
17 Aug 2026NeedhamInitiatesBuy—
10 Aug 2026Canaccord GenuityMaintainsBuy$32 → $43
10 Aug 2026Canaccord GenuityMaintainsBuy—
4 June 2026Canaccord GenuityInitiatesBuy$32
4 June 2026Canaccord GenuityInitiatesBuy—
7 July 2025OppenheimerInitiatesOutperform—
21 Sept 2022Maxim GroupDowngradeHold—
13 May 2022HC Wainwright & Co.DowngradeNeutral—
1 Apr 2022HC Wainwright & Co.MaintainsBuy—
1 Apr 2022Stephens & Co.MaintainsOverweight—
10 Feb 2022HC Wainwright & Co.MaintainsBuy—
16 Nov 2021HC Wainwright & Co.MaintainsBuy—
27 July 2021Stephens & Co.InitiatesOverweight—
11 Mar 2021Maxim GroupInitiatesBuy—
26 Jan 2021HC Wainwright & Co.MaintainsBuy—
12 May 2020H.C. WainwrightUpgradeBuy—
12 May 2020HC Wainwright & Co.UpgradeBuy—
14 Feb 2020H.C. WainwrightDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLSE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PLSE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Pulse Biosciences, Inc. returned +273.3% against +17.0% for the S&P 500, dividends included.

PLSE vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250300350400Oct 25Jan 26Apr 26Jul 26PLSES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLSE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Pulse Biosciences, Inc. (PLSE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−50.2×

Cheaper than 98% of US stocks

Price / sales
3262.8×

Cheaper than 1% of US stocks

Price / book
38.6×

Cheaper than 3% of US stocks

EV / EBITDA
−45.6×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
8.2%

Higher than 47% of US stocks

Earnings growth (YoY)
—
Gross margin
37.1%

Higher than 45% of US stocks

Operating margin
−5823.0%

Higher than 3% of US stocks

Net margin
−54.0%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−78.5%

Higher than 16% of US stocks

Return on assets
−44.3%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pulse Biosciences, Inc. (PLSE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pulse Biosciences, Inc. has a market value of $3.9B and an enterprise value of $3.8B.

  • Revenue in the twelve months to 30 June 2026: $1.2M. The latest quarter grew 8.2% year on year.

  • Net income over the same four quarters: −$80.1M, a −6755.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.18.

  • Free cash flow in the twelve months to 30 June 2026: −$61.4M.

  • Shares outstanding: 70.8M.

  • Trailing P/E: −50.2×; forward P/E: −47.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Pulse Biosciences, Inc. employs 116 people — $10K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

PLSE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
PLSEPulse Biosciences, Inc.$3.9B
42
ICUIICU Medical, Inc.$3.9B
97
NVSTEnvista Holdings Corp.$4.3B
98
WRBYWarby Parker, Inc.$3.1B
28
ATRCAtriCure, Inc.$2.8B
94
MMSIMerit Medical Systems, Inc.$5.2B
93
TFXTeleflex, Inc.$5.8B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pulse Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLSE news & analysis

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Business Wire · 15 Sept 2026positive

Pulse Biosciences announced that enrollment has been completed in its PRECISE-BTN clinical study, which evaluates the nPulse Vybrance Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules. The company also noted that the first enrolled patient completed the final 12-month follow-up visit in August.

Why it matters — A PLSE watcher would care because these milestones advance the clinical evaluation of the company's nPulse nanosecond PFA technology for benign thyroid nodules, moving the study toward completed follow-up and potential regulatory evidence.

Why Pulse Biosciences Stock Popped Today

The Motley Fool · 9 Sept 2026positive

An analyst initiated coverage of Pulse Biosciences with an unambiguous buy recommendation, citing a specific market that he believes is ripe for disruption by the company. The news drove the stock higher.

Why it matters — A fresh buy-rated analyst initiation and the prospect of a disruptive market opportunity could raise investor attention on Pulse Biosciences' prospects.

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 4 Sept 2026neutral

Pulse Biosciences announced that its Compensation Committee granted equity inducement awards to two new employees under its 2017 Inducement Equity Incentive Plan, outside of the company's 2017 Equity Incentive Plan. The equity awards were approved and issued.

Why it matters — PLSE watchers may take note of the new-hire equity grants as a routine step for employee retention and onboarding under Nasdaq listing rule compliance.

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 18 Aug 2026neutral

Pulse Biosciences announced that its Compensation Committee granted equity inducement awards to five new employees under the company's 2017 Inducement Equity Incentive Plan, outside its standard 2017 Equity Incentive Plan. The awards were approved and issued.

Why it matters — The grants signal continued hiring as Pulse Biosciences builds out its team around its proprietary Nanosecond Pulsed Field Ablation technology, keeping equity compensation in line with Nasdaq listing rules.

Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform

MarketBeat · 16 Aug 2026positive

Pulse Biosciences CEO and Co-Chairman Paul LaViolette presented at the Canaccord Genuity 46th Annual Global Growth Conference, positioning the company's nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions.

Why it matters — A PLSE watcher would care because the CEO's framing of the nanosecond PFA platform highlights its potential as a next-generation treatment for AFib, a key part of the company's growth strategy.

FAQ

Frequently asked questions about PLSE stock

What is the PLSE stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Pulse Biosciences, Inc. have a median 12-month price target of $45, with estimates ranging from $35 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PLSE stock a buy right now?

Of the 5 analysts covering Pulse Biosciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulse Biosciences, Inc. 42 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLSE?

As at 14 Sept 2026, Pulse Biosciences, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will PLSE stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -17.0% from the last close, and Ticker Nerd's factor model ranks Pulse Biosciences, Inc. 42 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PLSE stock forecast for 2030?

No analyst covering Pulse Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLSE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $73 over the next 12 months.

How has PLSE stock performed over the past year?

Pulse Biosciences, Inc. returned +273.3% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulse Biosciences, Inc. do?

Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows.

What is the latest news on PLSE?

The most recent item we track (Business Wire, 15 Sept 2026): "Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules". Pulse Biosciences announced that enrollment has been completed in its PRECISE-BTN clinical study, which evaluates the nPulse Vybrance Percutaneous Electrode System for the treatment of symptomatic benign thyroid nodules. The company also noted that the first enrolled patient completed the final 12-month follow-up visit in August.

Company

About Pulse Biosciences, Inc.

Pulse Biosciences Inc is a bioelectric medicine company focused on developing and commercializing medical technologies that use proprietary pulsed-field energy to treat targeted cells while preserving surrounding tissue. Its current product portfolio includes the nPulse System for benign skin lesions, the nPulse Vybrance Percutaneous Electrode system for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter System for circumferential cardiac ablation, and the nPulse Console, a software-enabled platform designed to support physician workflows. The company serves healthcare providers across dermatology, surgical soft-tissue care, and cardiac electrophysiology, with applications centered on minimally invasive treatment approaches. Pulse Biosciences Inc positions itself within the medical device market through its proprietary energy-based platform, which is designed for clinical use in areas where precise cellular targeting is important.

CEO Mr. Paul Arthur LaViolette M.B.A. · 116 employees · United States · https://www.pulsebiosciences.com